Drug Class Description

Non-sulphonylureas.
Generic Name

Repaglinide
Drug Description

0.5 mg white tablet; 1 mg yellow tablet; 2 mg red tablet. All marked with company logo.
Presentation

Tablets, repaglinide 0.5 mg , 1 mg , 2 mg .
Indications

Non-insulin dependent (type II) diabetes uncontrolled by diet or exercise. In combination with metformin where control of hyperglycaemia is not satisfactory.

Adult Dosage

Initially 0 .5 mg, 15 - 30 minutes before each main meal. Titrate at 1 - 2 week intervals according to response. Maximum 4 mg as single dose before each main meal; maximum total daily dose, 16 mg. If transferring from another oral hypoglycaemic, start therapy with 1 mg before each main meal.

Child Dosage

Under 18 years, not recommended.
Elderly Dosage

Over 75 years, not recommended.
Contra Indications

Type I diabetes, diabetic acidosis, severe renal or hepatic acidosis, severe renal or hepatic impairment. Pregnancy, lactation.

Special Precautions

Periodically monitor blood glucose and glycosylated haemoglobin.
Interactions

MAOIs, b-blockers, ACE inhibitors, salicylates, NSAIDs, octreotide, alcohol, anabolic steroids, oral contraceptives, thiazide diuretics, corticosteroids, danazol, thyroid hormones, sympathomimetics, rifampicin, simvastatin.

Adverse Reactions

Hypoglycaemia, visual disturbances, GI upset, rash, transient elevation in liver enzymes.
Manufacturer

Novo Nordisk
Drug Availability

(POM)
Updated

29 June 2009